The talk focuses on the evidence for short- and long-term benefits of achieving and maintaining glycemic control in patients with T2D, and discusses options for lifestyle and medication management to achieve such control. Randomized controlled trials that will provide new information about optimal management approaches, such as the NIH's GRADE trial, will be discussed. In particular, the results of recent Cardiovascular Outcomes Trials for newer diabetes medications highlight the importance of CV prevention in patients with T2DM.
Join expert faculty for a comprehensive, case-based discussion on insulin therapy. This interactive activity will examine insulin initiation, available and emerging insulin options, ways to overcome barriers to insulin, how and when to advance therapy, and practical tips to prevent and treat hypoglycemia.
In this Expert Perspective, Dr. Vanita Aroda answers important questions about the benefits and use of ultra-long-acting insulins as well as ways to overcome the therapeutic inertia associated with initiating and intensifying insulin therapy.
In this talk, the speaker will discuss goals of treatment as it relates to microvascular complication risk reduction and reasons for using insulin in specific populations, focusing on type 2 diabetes. Additionally, learners will review currently available short- and long-acting insulins on the U.S. market and associated risks and benefits of use. Finally, the speaker will expand on the practical use of insulin (i.e., when to start, how to titrate, etc.).
This case discusses treatment intensification with the combination of a GLP-1 RA and basal insulin in a patient with uncontrolled T2DM. Treatment decisions will include individualized HbA1c guideline recommendations, patient preference, cardiovascular risk, and other comorbidities such as visual impairment.
New therapeutic options have emerged in the type 2 diabetes (T2DM) management paradigm that improve hyperglycemic control while decreasing cardiovascular risk. Watch this expert-led 90-minute panel discussion to learn about exciting new research on cardiovascular outcomes studies of antidiabetic agents and the resultant practical applications for patient care. Participants in this program will also receive expert advice on using ADA and AACE/ACE guidelines appropriately as well as other strategic insights to improve care for their patients with T2DM and cardiovascular risk.
This activity is part of the ConnectED Learning: Diabetes curriculum. Join expert faculty as they address your remaining questions and provide a distillation of clinical pearls from the ConnectED Learning Curriculum on the management of diabetes
This case follows treatment intensification in a patient with T2DM that remains uncontrolled on oral therapy. Participants will consider ways to overcome barriers to injectable therapy, advance to combination injectable therapy, and determine the best fixed-ratio GLP-1 RA/basal insulin formulation based on the patient’s blood glucose readings.
This activity is part of the ConnectED Learning: Diabetes curriculum. It is well proven that effective glycemic control among patients with type 2 diabetes can reduce the risk of diabetes-related microvascular and macrovascular complications. This dynamic live educational program will feature renowned faculty experts who will lead an interactive discussion on important evidence supporting emerging clinical strategies, shared decision making, and ways in which to individualize care to best manage the complex challenges of diabetes and the progression of disease. It will include therapeutic approaches that can reduce the risks such as hypoglycemia, weight gain, and cardiovascular events.
The past year has seen a number of changes in the pharmaceutical landscape, including the introduction of a new class of cholesterol-lowering agents and changes in the prescribing information for several commonly used agents, including those for diabetes and insomnia. Gerald Smetana, Professor of Medicine at Harvard Medical School, reviews some important new information regarding several agents commonly prescribed by primary care clinicians.
This case examines the management of a patient experiencing episodes of nocturnal hypoglycemia on premixed and prandial insulin. Areas of concentration include switching to ultra-long-acting basal insulin (including dose conversions), hypoglycemia self-management, depression and anxiety in patients with diabetes, and lipodystrophy.
It is well proven that effective glycemic control among patients with type 2 diabetes can reduce the risk of diabetes-related microvascular and macrovascular complications. This dynamic and interactive live educational program will feature renowned faculty experts who will lead an interactive discussion of important evidence supporting the use of individualized oral combination therapy to attain glycemic control while minimizing weight gain, as well as hypoglycemic and CV risk.